Synthesis, structure-activity relationships, and in vivo properties of 3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-ones as corticotropin-releasing factor-1 receptor antagonists

被引：13

作者：

Dzierba, CD ^{[1
]}

Takvorian, AG ^{[1
]}

Rafalski, M ^{[1
]}

Kasireddy-Polam, P ^{[1
]}

Wong, H ^{[1
]}

Molski, TF ^{[1
]}

Zhang, G ^{[1
]}

Li, YW ^{[1
]}

Lelas, S ^{[1
]}

Peng, Y ^{[1
]}

McElroy, JF ^{[1
]}

Zaczek, RC ^{[1
]}

Taub, RA ^{[1
]}

Combs, AP ^{[1
]}

Gilligan, PJ ^{[1
]}

Trainor, GL ^{[1
]}

机构：

[1] Bristol Myers Squibb Co, Pharmaceut Res Inst, Wallingford, CT 06492 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2004年 / 47卷 / 23期

关键词：

D O I：

10.1021/jm049737f

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Corticotropin releasing factor (CRF) is the primary regulator of the hypothalamus-pituitary-adrenal (HPA) axis, coordinating the endocrine, behavioral, and autonomic responses to stress. It has been postulated that small molecules that can antagonize the binding of CRF, to its receptor may serve as a treatment for anxiety-related and/or affective disorders. Members within a series of 3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-ones, exemplified by compound 2 (IC50 = 0.70 nM), were found to be very potent antagonists of CRF1. Compound 8w showed high CRF1 receptor binding affinity and was examined further in vivo. The compound was efficacious in a defensive withdrawal model of anxiety in rats and had a long half-life and reasonable oral bioavailability in dog pharmacokinetic studies.

引用

页码：5783 / 5790

页数：8

共 34 条

[11] CSF CORTICOTROPIN-RELEASING FACTOR-LIKE IMMUNOACTIVITY IN CHRONIC PAIN PATIENTS WITH AND WITHOUT MAJOR DEPRESSION
FRANCE, RD
URBAN, B
KRISHNAN, KRR
BISSETT, G
BANKI, CM
NEMEROFF, C
SPEILMAN, FJ
[J]. BIOLOGICAL PSYCHIATRY, 1988, 23 (01) : 86 - 88
[12] Corticotropin-releasing hormone (CRH) receptors and the discovery of selective non-peptide CRH1 antagonists
Gilligan, PJ
Hartig, PR
Robertson, DW
Zaczek, R
[J]. ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 32, 1997, 32 : 41 - 50
[13] Corticotropin releasing factor (CRF) receptor modulators: Progress and opportunities for new therapeutic agents
Gilligan, PJ
Robertson, DW
Zaczek, R
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (09) : 1641 - 1660
[14] RESPONSES TO CORTICOTROPIN-RELEASING HORMONE IN THE HYPERCORTISOLISM OF DEPRESSION AND CUSHINGS-DISEASE - PATHOPHYSIOLOGIC AND DIAGNOSTIC IMPLICATIONS
GOLD, PW
LORIAUX, DL
ROY, A
KLING, MA
CALABRESE, JR
KELLNER, CH
NIEMAN, LK
POST, RM
PICKAR, D
GALLUCCI, W
AVGERINOS, P
PAUL, S
OLDFIELD, EH
CUTLER, GB
CHROUSOS, GP
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (21) : 1329 - 1335
[15] GOLD PW, 1984, AM J PSYCHIAT, V141, P619
[16] Griebel G, 1998, PSYCHOPHARMACOLOGY, V138, P55
[17] ACTH AND MULTISTEROID RESPONSES TO CORTICOTROPIN-RELEASING FACTOR IN DEPRESSIVE-ILLNESS - RELATIONSHIP TO MULTISTEROID RESPONSES AFTER ACTH STIMULATION AND DEXAMETHASONE SUPPRESSION
HOLSBOER, F
MULLER, OA
DOERR, HG
SIPPELL, WG
STALLA, GK
GERKEN, A
STEIGER, A
BOLL, E
BENKERT, O
[J]. PSYCHONEUROENDOCRINOLOGY, 1984, 9 (02) : 147 - 160
[18] Receptor occupancy of nonpeptide corticotropin-releasing factor 1 antagonist DMP696: Correlation with drug exposure and anxiolytic efficacy
Li, YW
Hill, G
Wong, H
Kelly, N
Ward, K
Pierdomenico, M
Ren, S
Gilligan, P
Grossman, S
Trainor, G
Taub, R
McElroy, J
Zazcek, R
[J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 305 (01) : 86 - 96
[19] LIANG KC, 1992, J NEUROSCI, V12, P2303
[20] Antidepressant-like effects of CP-154,526, a selective CRF(1) receptor antagonist
Mansbach, RS
Brooks, EN
Chen, YL
[J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 323 (01) : 21 - 26

← 1 2 3 4 →